4D Molecular Therapeutics, Inc. (FDMT)
NASDAQ: FDMT · Real-Time Price · USD
10.70
-0.49 (-4.38%)
At close: Dec 5, 2025, 4:00 PM EST
10.91
+0.21 (1.96%)
After-hours: Dec 5, 2025, 7:24 PM EST
4D Molecular Therapeutics Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for 4D Molecular Therapeutics stock have an average target of 30.33, with a low estimate of 6.00 and a high estimate of 40. The average target predicts an increase of 183.46% from the current stock price of 10.70.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for 4D Molecular Therapeutics stock from 9 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 4 | 3 | 3 | 4 | 4 | 4 |
| Hold | 1 | 1 | 1 | 0 | 0 | 0 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 9 | 9 | 9 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Maintains $26 → $32 | Buy | Maintains | $26 → $32 | +199.07% | Nov 11, 2025 |
| Barclays | Barclays | Buy Maintains $38 → $33 | Buy | Maintains | $38 → $33 | +208.41% | Nov 11, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $25 → $26 | Strong Buy | Maintains | $25 → $26 | +142.99% | Nov 11, 2025 |
| RBC Capital | RBC Capital | Buy Reiterates $26 | Buy | Reiterates | $26 | +142.99% | Oct 21, 2025 |
| Roth Capital | Roth Capital | Strong Buy Maintains $44 → $38 | Strong Buy | Maintains | $44 → $38 | +255.14% | Aug 12, 2025 |
Financial Forecast
Revenue This Year
7.87M
from 37.00K
Increased by 21,181.08%
Revenue Next Year
20.66M
from 7.87M
Increased by 162.43%
EPS This Year
-3.75
from -2.98
EPS Next Year
-3.55
from -3.75
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 19.0M | 53.9M | ||||
| Avg | 7.9M | 20.7M | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 51,264.9% | 584.1% | ||||
| Avg | 21,181.1% | 162.4% | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -3.47 | -2.73 | ||||
| Avg | -3.75 | -3.55 | ||||
| Low | -3.82 | -4.21 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.